Wandong Medical announced 1.931 billion overseas acquisitions

December 8, Wandong Medical announced the progress of its investment in Esaote, Italy's world-renowned medical device group, in a merger fund. On December 6, the Company received a notice from the Partnership that the Partnership and Yum Medical Group had signed an Equity Purchase Agreement to purchase all of Yum Medical's shares, excluding inventory shares, from the transferor for EUR 248 million.
The focus of this merger is that this is fish leap technology to take Wandong Holdings, and then the introduction of Alibaba Jack Aura Yunfeng Yunfeng fund, and then in April this year to pull the United States New Year's Health founder Yu Fu as the second largest shareholder, Wandong shot the first major merger and acquisition transaction, and hit the foreign mature medical device target, the amount of about 1.931 billion yuan.
clearly, this is a merger tailored for Wandong. Wandong, which has become one of the world's largest manufacturers of radiographic equipment, has an annual output of more than 6000 sets of X-ray equipment production capacity, products covering medical X-ray diagnostic equipment, magnetic resonance imaging equipment in the field of a number of categories, of which the domestic market share of popular products reached more than 50%.1, Who's Yum? Why buy it?
Yum Medical was founded in 1983 as an internationally renowned multinational company for high-end medical devices, with core products including ultrasound medical imaging solutions and dedicated MRI systems, according to Wandong Medical Bulletin. In the field of ultrasound imaging, Yum Medical Group has mastered the core technology of the entire industrial chain, has the ability to independently develop core components, and is in the leading position in the world in ultrasound imaging, interventional therapy and high-frequency imaging.
Medical Group is headquartered in Italy, with manufacturing plants and research and development facilities in Genoa, Florence and Maastricht in the Netherlands. Through its international distribution network, Yum operates in more than 60 countries and is the world's leading medical device manufacturer, ranking sixth among the world's top 10 ultrasound equipment suppliers, with the largest market share in Italy and Spain, an absolute global leader in the specialist MRI segment, with a 30% market share and more than 180 patents in color ultrascopic, ultrasound probes, dedicated MRI and medical imaging software.
audited key financial data for the business as at 31 December 2016 showed total assets of EUR 474.4 million, liabilities of EUR 276.5 million, total operating income of EUR 270 million, operating profit of EUR 15.9 million and net profit of EUR 5.2 million in 2016.
for participating in the merger fund, Wandong Medical said that participating in the merger and acquisition fund will help the company to further integrate and utilize the advantages of the partners resources, is conducive to the company's industrial chain integration and expansion. At the same time, the use of the merger and acquisition fund platform, layout and the company's main business has relevance, synergy, in line with the company's development strategy of high-quality projects, will be conducive to the company in the field of medical devices to cultivate new profit growth points, further enhance the company's related product development, production and sales of competitiveness, accelerate the company's expansion in the industry, enhance the company's profitability.
said the deal would boost Yum's growth plans and rapidly break into the fast-growing Chinese medical device market. Upon completion of this acquisition, Yum Medical will continue to operate independently as a global manufacturer of medical devices, and Mr. Karl-Heinz Lumpi, Chief Executive Officer of Yum Medical, will remain in office.
In addition, Yum Medical also said that Yum can increase its penetration in China's medical imaging equipment market through Wandong, Fish Leap, Meiying, Konda and other large distribution networks and procurement channels, while Yum can also help Wandong, Fish Leap, Konda distribute its products in the international market, to help domestic medical products to go international. The deal is expected to close in early 2018, according to Yum Healthcare.2, the high-profile three-person portfolio
Jack Ma, Mr. Wu, and Mr. Yu are the three most-watched people in the buyers' alliance, and their relationship with Wandong Medical is as follows:
Yunfeng Fund, founded by Mr. Ma and considered a medical investment fund owned by Mr. Ali, paid 200 million yuan in a private placement in June 2015 to subscribe for 2.35 percent of Thedong's shares, or about 5.7 million shares.
Fish Leap Medical, founded by Wu Guangming, announced in April 2015 that the controlling company Fish Leap Technology's acquisition of a 51.51% stake in China Resources Wandong, a limited liability company of Beijing Pharmaceutical Group Co., Ltd., had been transferred to the company and became the controlling shareholder of Wandong.
And the actual controller of American Health, Yu Fu, through its name Tian billion group, in April 2017 for 1,657 million yuan from the controlling shareholder Fish Leap Technology to obtain a 22% stake in Wandong Medical, becoming The second largest shareholder of Wandong Medical. Tian billion Group was founded in 1998, earlier than 2006 to create the United States Health.
Tian billion Group's total assets in 2016 were RMB8,323 million, net assets were RMB4,054 million, operating income was RMB3,144 million and net profit was RMB344 million.
On why we are investing in Wandong Medical, at the May 5 shareholders' meeting, Yu said cautiously that the investment is based on the foundation of Wandong Medical, Wu Guangming's influence in the medical industry recognition, the future health industry still needs to develop in concert. Wandong Medical has become the representative of the country's high-end medical devices, this investment is also based on the company's long-term development.
Wandong Medical introduction, fish leap technology through the transfer of agreements to introduce the transfer party as a strategic partner, hope to give full play to the rich professional experience and resources in the medical service industry, optimize the company management and resource allocation, improve the corporate governance structure, and further enhance the listed companies' ability to continue to operate, profitability and industry competitiveness.
For the cooperation between the two sides, Southwest Securities believes that most of the U.S. health centers are carrying out imaging diagnostic business, is expected to form synergies with Wandong Medical's imaging diagnostic devices;
From the implementation of the merger of Shanghai Land Management Consulting Center (Limited Partnership) equity structure can be seen in one of the three:
Fish Leap Technology, Tian billion Group, Shanghai Yunfeng Yan Investment Center, Shanghai Free Trade Pilot Zone Phase III Equity Investment Fund Partnership, Shanghai Kangda Medical Devices Group Co., Ltd., Ningbo Xinda Huajian Investment Co., Ltd. as a limited partner, Shanghai Free Trade Zone Equity Investment Fund Management Co., Ltd. as a general partner and fund manager, will act as the operation of the merger. Among them, Wandong Medical, Fish Leap Technology and Tian billion Group contributed 280 million yuan, 266 million yuan and 249 million yuan, respectively, 79.6 million yuan, and the proportion of contributions paid was 17.9999 percent, 17.0999 percent and 15.9999 percent, respectively.
the country's continuous introduction of a good third-party medical imaging services policy stimulus, some securities analysts pointed out that the size of the domestic imaging market has now reached more than 200 billion yuan. With Wu Guangming, who is good at capital operation, and Yu Fu's holdings, the merger and acquisition drama of giant Wandong Medical may have just begun. (E drug manager)